Apogee Therapeutics, Inc. (APGE)
NGM – Real Time Price. Currency in USD
132.55
-0.13 (-0.10%)
At close: Jun 26, 2026, 4:00 PM EDT
132.75
+0.20 (0.15%)
After-hours: Jun 26, 2026, 6:10 PM EDT
Find any stock by ticker or company name

NGM – Real Time Price. Currency in USD
132.55
-0.13 (-0.10%)
At close: Jun 26, 2026, 4:00 PM EDT
132.75
+0.20 (0.15%)
After-hours: Jun 26, 2026, 6:10 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Company's cash reserves $451.8M significantly exceed its total debt $8.0M, ensuring strong financial flexibility
Total current assets $1.1B exceed Total current liabilities $33.0M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$55.6M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 32.59 | 6.05 | 10 | |
| Quick ratio | 32.59 | 5.63 | 10 | |
| Debt to Equity | 0.01 | 0.30 | 10 | |
| Debt to Assets | 0.01 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | -189K | -1M | -2M |
| Operating Income | -31M | -93M | -217M | -286M | -305M |
| Net Income | -40M | -84M | -182M | -256M | -275M |
| EBITDA | -31M | -93M | -217M | -284M | -304M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 5.1 | 3.0 |
| Next quarter | N/A | -1.3 | 1.0 |
| Current year | N/A | -3.85 | 1.0 |
| Next year | N/A | -22.1 | 1.0 |
| Weighted average score | 1.5 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -6.8 | -2.9 | 11.44 | 4.8 |
| Y/Y | 999 | -33.91 | -11.57 | -5.25 | 3.3 |
| 3y average | 999 | -89.46 | -13.03 | -173.68 | 3.3 |
| 5y average | N/A | N/A | N/A | N/A | 1.0 |
| Weighted average score | 3.1 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |